 <h1>Hyaluronidase / pertuzumab / trastuzumab Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to hyaluronidase/pertuzumab/trastuzumab: subcutaneous solution</i></p><h3>Warning</h3><p>This medicine can cause life-threatening heart or lung problems. Call your doctor at once if you have trouble breathing, swelling or rapid weight gain, fast or pounding heartbeats, or if you feel light-headed.</p><p>Do not use if you are pregnant.  Use effective birth control during treatment and for at least 7 months after your last dose.</p><p>Get emergency medical help if you have signs of an allergic reaction:  hives, rash; fever, chills, dizziness; nausea, vomiting, diarrhea; chest pain, difficult breathing; swelling of your face, lips, tongue, or throat.</p><p>This medicine can cause life-threatening heart or lung problems. Call your doctor at once if you have:</p><ul>
<li>
<p>a new or worsening cough or shortness of breath (even while at rest);</p>
</li>
<li>
<p>fast or pounding heartbeats;</p>
</li>
<li>
<p>severe headache, blurred vision, pounding in your neck or ears;</p>
</li>
<li>
<p>swelling in your face or lower legs;</p>
</li>
<li>
<p>rapid weight gain (more than 5 pounds in 24 hours);</p>
</li>
<li>
<p>a light-headed feeling, like you might pass out;</p>
</li>
<li>
<p>low white blood cell counts--fever, mouth sores, skin sores, sore throat, cough, trouble breathing; or</p>
</li>
<li>
<p>low red blood cells (anemia)--pale skin, unusual tiredness, feeling light-headed or short of breath, cold hands and feet.</p>
</li>
</ul><p>a new or worsening cough or shortness of breath (even while at rest);</p><p>fast or pounding heartbeats;</p><p>severe headache, blurred vision, pounding in your neck or ears;</p><p>swelling in your face or lower legs;</p><p>rapid weight gain (more than 5 pounds in 24 hours);</p><p>a light-headed feeling, like you might pass out;</p><p>low white blood cell counts--fever, mouth sores, skin sores, sore throat, cough, trouble breathing; or</p><p>low red blood cells (anemia)--pale skin, unusual tiredness, feeling light-headed or short of breath, cold hands and feet.</p><p>Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.</p><p>Common side effects may include:</p><ul>
<li>
<p>nausea, diarrhea;</p>
</li>
<li>
<p>anemia;</p>
</li>
<li>
<p>feeling weak or tired;</p>
</li>
<li>
<p>hair loss;</p>
</li>
<li>
<p>rash; or</p>
</li>
<li>
<p>numbness, tingling, or burning pain in your hands or feet.</p>
</li>
</ul><p>nausea, diarrhea;</p><p>anemia;</p><p>feeling weak or tired;</p><p>hair loss;</p><p>rash; or</p><p>numbness, tingling, or burning pain in your hands or feet.</p><p>This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. </p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to hyaluronidase / pertuzumab / trastuzumab: subcutaneous solution</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Hemoglobin low (90%), absolute lymphocytes low (89%), leukocyte count low (82%), neutrophils low (68%), anemia (36%), platelets low (27%), neutropenia (22%)</p><p><b>Common</b> (1% to 10%): Leukopenia, febrile neutropenia<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Influenza-like illness<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Radiation skin injury (19%), injection site reaction (15%), procedural pain (13%) </p><p><b>Common</b> (1% to 10%): Injection site pain<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Myalgia (25%), arthralgia (24%), pack pain (10%)</p><p><b>Common</b> (1% to 10%): Bone pain, pain in extremity, muscle spasms, musculoskeletal pain<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Lacrimation increased, dry eye<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite (17%), potassium low (17%), albumin low (16%), potassium high (13%), sodium low (13%), weight loss (11%)</p><p><b>Common</b> (1% to 10%): Hypokalemia, glucose low, sodium high<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (17%)<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Alanine aminotransferase high (58%), aspartate aminotransferase high (50%)</p><p><b>Common</b> (1% to 10%): Bilirubin high</p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (15%), epistaxis (12%), upper respiratory infection (11%), dyspnea (10%)</p><p><b>Common</b> (1% to 10%): Rhinorrhea, nasopharyngitis, paronychia</p><p><b>Frequency not reported</b>: Dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, pulmonary insufficiency/hypoxia, acute respiratory distress syndrome, pulmonary fibrosis, exacerbation of chemotherapy-induced neutropenia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Asthenia (31%), fatigue (29%), pyrexia (13%)</p><p><b>Common</b> (1% to 10%): Edema peripheral, malaise</p><p><b>Frequency not reported</b>: Embryofetal toxicity<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Dysgeusia (17%), headache (17%), peripheral sensory neuropathy (16%), peripheral neuropathy (12%), dizziness (13%), paresthesia (10%)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Creatinine high (84%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hot flush (12%), left ventricular cardiac dysfunction (LVEF)</p><p><b>Common</b> (1% to 10%): Ejection fraction decreased</p><p><b>Frequency not reported</b>: Hypertension, arrhythmias, left ventricular cardiac dysfunction, disabling cardiac failure, cardiomyopathy, cardiac death<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Alopecia (77%), rash (16%), dry skin (15%)</p><p><b>Common</b> (1% to 10%): Nail discoloration, erythema, dermatitis, nail disorder, palmar-plantar erythrodysesthesia syndrome</p><p><b>Uncommon</b> (0.1% to 1%): Pruritus<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (60%), diarrhea (60%), stomatitis (25%), constipation (22%), vomiting (20%), mucosal inflammation (15%), dyspepsia (14%)</p><p><b>Common</b> (1% to 10%): Hemorrhoids, abdominal pain, abdominal pain upper<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Phesgo (hyaluronidase / pertuzumab / trastuzumab)." Genentech, South San Francisco, CA. </p><h2>More about hyaluronidase / pertuzumab / trastuzumab</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: HER2 inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Pertuzumab, trastuzumab, and hyaluronidase-zzxf Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Breast Cancer</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>